Search
UCB7362
go.drugbank.com/drugs/DB17096Experimentalin mice) studies. … UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria.
Pipecuronium
go.drugbank.com/drugs/DB01338ApprovedInvestigationalWithdrawnPipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.
Besifovir dipivoxil
go.drugbank.com/drugs/DB05020InvestigationalBesifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhib...
Beraprost
go.drugbank.com/drugs/DB05229InvestigationalIt is also being studied for use in avoiding reperfusion injury.
Tozorakimab
go.drugbank.com/drugs/DB16473InvestigationalTozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in
Roxarsone
go.drugbank.com/drugs/DB11458ExperimentalVet approvedThe drug is also approved in the United States for use in pigs. … Roxarsone is an organoarsenic molecule added to poultry feed.
International brands: Ren-O-SalFluciclatide
go.drugbank.com/drugs/DB14842InvestigationalFluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis. … The conditions targeted by [18F]Fluciclatide in these studies include high-grade glioma, lung cancer, and kidney neoplasms
AEM-28-14
go.drugbank.com/drugs/DB17643ExperimentalAEM-28-14 is an analog of [AEM-28], an apolipoprotein E mimetic peptide, with a 400 percent greater cholesterol-lowering efficacy and a several-fold increase in drug tolerability.
Pegsitacianine
go.drugbank.com/drugs/DB19098InvestigationalPegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence … Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)).